Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Effectiveness of Different Targeted Therapies for BRAF-mutated Unresectable/Metastatic Melanoma in the United States

NCT05260684 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05260684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05260684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Effectiveness of Different Targeted Therapies for BRAF-mutated Unresectable/Metastatic Melanoma in the United States
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
January 17, 2022
Completion date
December 31, 2023
Enrollment
716 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma